The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project
Open accessAbstract
Purpose: In contrast to Hodgkin lymphoma and systemic anaplastic large-cell lymphoma, CD30 expression of malignant lymphocytes in mycosis fungoides (MF) and Sézary syndrome (SS) is quite variable. Clinical activity and safety of brentuximab vedotin, a CD30 targeting antibody-drug conjugate, was evaluated in MF and SS. Tissue and blood biomarkers of clinical response were explored. Patients and Methods: In this phase II study, patients with MF or SS with negligible to 100% CD30 expression levels were treated with brentuximab vedotin (1.8 mg/kg) every 3 weeks for a maximum of sixteen doses. The primary end point was overall global response rate. Secondary end points included correlation of tissue CD30 expression level with clinical response, time to response, duration of response, progression-free and event-free survivals, and safety. Results: Of the 32 patients enrolled and treated, 30 patients had available efficacy evaluations. Objective global response was observed in 21 (70%) of 30 patients (90% CI, 53% to 83%). CD30 expression assessed by immunohistochemistry was highly variable, with a median CD30 max of 13% (range, 0% to 100%). Those with <5% CD30 expression had a lower likelihood of global response than did those with 5% or greater CD30 expression (P < .005). CD163 positive tumor-associated macrophages, many of which coexpress CD30, were abundant in tissue. Peripheral neuropathy was the most common adverse event. Conclusion: Brentuximab vedotin demonstrated significant clinical activity in treatment-refractory or advanced MF or SS with a wide range of CD30 expression levels. Additional biomarker studies may help optimize rational design of combination therapies with brentuximab vedotin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Olsen, E., Vonderheid, E., Pimpinelli, N., Willemze, R., Kim, Y., Knobler, R., Zackheim, H., Duvic, M., Estrach, T., Lamberg, S., et al. (2007) · Blood · doi:10.1182/blood-2007-03-055749 · Cited by 1,429
Self-citationTumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Steidl, C., Lee, T., Shah, S. P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S. J., Iqbal, J., Weisenburger, D. D., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905680 · Cited by 1,262
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2434 · Cited by 1,055
Self-citationPro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0402 · Cited by 997
Self-citationThiers, B. H. (2008) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70989-4 · Cited by 974
Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0039 · Cited by 931
Piekarz, R. L., Frye, R., Turner, M., Wright, J. J., Allen, S. L., Kirschbaum, M. H., Zain, J., Prince, H. M., Leonard, J. P., Geskin, L. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6150 · Cited by 740
Olsen, E. A., Whittaker, S., Kim, Y. H., Duvic, M., Prince, H. M., Lessin, S. R., Wood, G. S., Willemze, R., Demierre, M.-F., Pimpinelli, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.0630 · Cited by 666
Self-citationWhittaker, S. J., Demierre, M.-F., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., Scarisbrick, J., Reddy, S., Robak, T., Becker, J. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9066 · Cited by 664
Self-citationCarreras, J., Lopez-Guillermo, A., Fox, B. C., Colomo, L., Martinez, A., Roncador, G., Montserrat, E., Campo, E., & Banham, A. H. (2006) · Blood · doi:10.1182/blood-2006-04-018218 · Cited by 503
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., Kim, Y. H., Hoppe, R. T., Knox, S. J., Shin, L. K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9793 · Cited by 487
Self-citationIntracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Okeley, N. M., Miyamoto, J. B., Zhang, X., Sanderson, R. J., Benjamin, D. R., Sievers, E. L., Senter, P. D., & Alley, S. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2069 · Cited by 393
Ogura, M., Ishida, T., Hatake, K., Taniwaki, M., Ando, K., Tobinai, K., Fujimoto, K., Yamamoto, K., Miyamoto, T., Uike, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.0924 · Cited by 362
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
Horwitz, S. M., Advani, R. H., Bartlett, N. L., Jacobsen, E. D., Sharman, J. P., O’Connor, O. A., Siddiqi, T., Kennedy, D. A., & Oki, Y. (2014) · Blood · doi:10.1182/blood-2013-12-542142 · Cited by 352
Self-citationChetaille, B., Bertucci, F., Finetti, P., Esterni, B., Stamatoullas, A., Picquenot, J. M., Copin, M. C., Morschhauser, F., Casasnovas, O., Petrella, T., et al. (2009) · Blood · doi:10.1182/blood-2008-07-168096 · Cited by 250
Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases
Benner, M. F., Jansen, P. M., Vermeer, M. H., & Willemze, R. (2012) · Blood · doi:10.1182/blood-2011-08-376319 · Cited by 215
Tan, K. L., Scott, D. W., Hong, F., Kahl, B. S., Fisher, R. I., Bartlett, N. L., Advani, R. H., Buckstein, R., Rimsza, L. M., Connors, J. M., et al. (2012) · Blood · doi:10.1182/blood-2012-04-421057 · Cited by 208
Self-citationHoppe, R. T., Medeiros, L. J., Warnke, R. A., & Wood, G. S. (1995) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(95)90067-5 · Cited by 182
Self-citationWu, X., Schulte, B. C., Zhou, Y., Haribhai, D., Mackinnon, A. C., Plaza, J. A., Williams, C. B., & Hwang, S. T. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.206 · Cited by 137
Nam, S. J., Go, H., Paik, J. H., Kim, T., Heo, D. S., Kim, C. W., & Jeon, Y. K. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.879713 · Cited by 126
CD30 Expression and Proliferative Fraction in Nontransformed Mycosis Fungoides
Edinger, J. T., Clark, B. Z., Pucevich, B., Geskin, L. J., & Swerdlow, S. H. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181bf677d · Cited by 117
Vermeer, M. H., van Doorn, R., Dukers, D. F., Bekkenk, M. W., Meijer, C. J. L. M., & Willemze, R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.23.4322 · Cited by 113
Sugaya, M., Miyagaki, T., Ohmatsu, H., Suga, H., Kai, H., Kamata, M., Fujita, H., Asano, Y., Tada, Y., Kadono, T., et al. (2012) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2012.07.007 · Cited by 108
Weng, W., Armstrong, R. J., Arai, S., Desmarais, C., Hoppe, R. T., & Kim, Y. H. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007420 · Cited by 107
Self-citationSundram, U. N., Harvell, J. D., Rouse, R. V., & Natkunam, Y. (2003) · Modern Pathology · doi:10.1097/01.mp.0000081726.49886.cf · Cited by 101
Self-citationLack of Suppressive CD4+CD25+FOXP3+ T Cells in Advanced Stages of Primary Cutaneous T-Cell Lymphoma
Tiemessen, M. M., Mitchell, T. J., Hendry, L., Whittaker, S. J., Taams, L. S., & John, S. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700371 · Cited by 99
Visualization of Microscopy‐Based Spectral Imaging Data from Multi‐Label Tissue Sections
Mansfield, J. R., Hoyt, C. C., & Levenson, R. M. (2008) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb1419s84 · Cited by 86
Ni, X., Hazarika, P., Zhang, C., Talpur, R., & Duvic, M. A. (2001) · PubMed · Cited by 60
Bartlett, N. L., Sharman, J. P., Oki, Y., et al. (2013) · Blood · doi:10.1182/blood.v122.21.848.848 · Cited by 49
Specific Inhibition Of Ectodomain Shedding Of GPIba By Targeting Its Shedding Cleavage Site
Liang, X., Russell, S., Estelle, S., et al. (2013) · Blood · doi:10.1182/blood.v122.21.21.21 · Cited by 33
Cited by
Kim, Y. H., Bagot, M., Pinter-Brown, L., Rook, A. H., Porcu, P., Horwitz, S. M., Whittaker, S., Tokura, Y., Vermeer, M., Zinzani, P. L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30379-6 · Cited by 669
Self-citationPrince, H. M., Kim, Y. H., Horwitz, S. M., Dummer, R., Scarisbrick, J., Quaglino, P., Zinzani, P. L., Wolter, P., Sanches, J. A., Ortiz-Romero, P. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31266-7 · Cited by 588
Self-citationTrautinger, F., Eder, J., Assaf, C., Bagot, M., Cozzio, A., Dummer, R., Gniadecki, R., Klemke, C.-D., Ortiz-Romero, P. L., Papadavid, E., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.027 · Cited by 452
Chen, R., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Connors, J. M., Engert, A., Larsen, E. K., Huebner, D., et al. (2016) · Blood · doi:10.1182/blood-2016-02-699850 · Cited by 395
Clemens, M. W., Jacobsen, E. D., & Horwitz, S. M. (2019) · Aesthetic Surgery Journal · doi:10.1093/asj/sjy331 · Cited by 336
Self-citation
Metadata
- Authors
- Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., Rozati, S., Nagpal, S., Krathen, M., Reddy, S., Hoppe, R. T., Nguyen-Lin, A., Weng, W.-K., Armstrong, R., Pulitzer, M., Advani, R. H., & Horwitz, S. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-11-10
- Volume
- 33
- Issue
- 32
- Pages
- 3750-3758
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2119799189
- Cited by
- 282
- References
- 31
- FWCI
- 32.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.